La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Esperion Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Esperion Therapeutics..

Esperion Therapeutics (NASDAQ:ESPR) Azioni, Catena delle Opzioni

ESPERION THERAPEUTICS INC

Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics Inc

ESPRIT HLDGS S/ADR by Esprit Holdings Ltd.

Esprit Holdings Ltd

ESPRE TECHNOLOGIES INC B by ESPRE TECHNOLOGIES INC

Espre Technologies Inc

ESPRIT HLDGS SHS TEMP by Esprit Holdings Ltd.

News

Management

Press Releases

Esperion Appoints Craig Thompson to Board of Directors

Health Care

Legal

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

Esperion to Report Second Quarter 2025 Financial Results on August 5

Earnings

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

HLS Therapeutics Announces Q2 2025 Financial Results

Esperion to Participate in Upcoming September Investor Conferences

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

ESPR

TSX:HLS

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

Alumis

ALT5 Sigma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Cormedix

Evolus

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

GH Research

High Tide

LB Pharmaceuticals

MBX Biosciences

Oculis Holding

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

scPharmaceuticals

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Comments

Esperion Therapeutics

Esperion Therapeutics (ESPR) Opzioni

Esperion Therapeutics (NASDAQ:ESPR) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO